基于胰高血糖素样肽-1的疗法：同时对抗2型糖尿病和肥胖症。
GLP-1 based therapeutics: simultaneously combating T2DM and obesity.
作者信息
Heppner Kristy M, Perez-Tilve Diego
机构信息
Division of Diabetes, Obesity and Metabolism, Oregon National Primate Research Center, Oregon Health and Science University Beaverton, OR, USA.
Department of Medicine, Metabolic Diseases Institute, University of Cincinnati Cincinnati, OH, USA.
出版信息
Front Neurosci. 2015 Mar 20;9:92. doi: 10.3389/fnins.2015.00092. eCollection 2015.
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic control as well as weight loss in type II diabetes (T2DM) patients treated with GLP-1R agonists. This is a superior advantage of GLP-1R pharmaceuticals as many other drugs used to treat T2DM are weight neutral or actual cause weight gain. This review summarizes GLP-1R action on energy and glucose metabolism, the effectiveness of current GLP-1R agonists on weight loss in T2DM patients, as well as GLP-1R combination therapies.
胰高血糖素样肽-1（GLP-1）可增强与进餐相关的胰岛素分泌，从而降低血糖波动。除了其肠促胰岛素作用外，GLP-1还作用于大脑中的GLP-1受体（GLP-1R）以抑制进食。GLP-1R信号传导的这些联合作用可改善血糖控制，并使接受GLP-1R激动剂治疗的II型糖尿病（T2DM）患者体重减轻。这是GLP-1R药物的一个显著优势，因为许多用于治疗T2DM的其他药物对体重无影响或实际上会导致体重增加。本文综述了GLP-1R对能量和葡萄糖代谢的作用、当前GLP-1R激动剂对T2DM患者体重减轻的有效性以及GLP-1R联合疗法。
Zotero 插件